A Multicenter, Randomized, Double-blind, Parallel Group, Placebo Controlled, Phase 3b Study to Evaluate the Safety and Efficacy of Benralizumab 30 mg sc in Patients With Severe Asthma Uncontrolled on Standard of Care Treatment

Trial Profile

A Multicenter, Randomized, Double-blind, Parallel Group, Placebo Controlled, Phase 3b Study to Evaluate the Safety and Efficacy of Benralizumab 30 mg sc in Patients With Severe Asthma Uncontrolled on Standard of Care Treatment

Recruiting
Phase of Trial: Phase III

Latest Information Update: 18 Oct 2017

At a glance

  • Drugs Benralizumab (Primary)
  • Indications Asthma
  • Focus Registrational; Therapeutic Use
  • Acronyms ANDHI
  • Sponsors AstraZeneca
  • Most Recent Events

    • 25 Jul 2017 Status changed from not yet recruiting to recruiting.
    • 05 Jun 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top